<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593681</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN 0507</org_study_id>
    <nct_id>NCT03593681</nct_id>
  </id_info>
  <brief_title>Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy</brief_title>
  <acronym>nCYT</acronym>
  <official_title>The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device&#xD;
      to collect cell samples from the fallopian tube that can be evaluated for the presence or&#xD;
      absence of malignancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">February 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement</measure>
    <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
    <description>Evaluate the sensitivity and specificity of the cytological samples collected from the fallopian tube in determining the presence or absence of malignancy for fallopian tube involvement as compared to the surgical histology results. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPV, NPV and Diagnostic Accuracy for Fallopian Tube Involvement</measure>
    <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
    <description>Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries and fallopian tube for fallopian tube involvement. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Fallopian Tube</measure>
    <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the fallopian tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Ovaries</measure>
    <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries for epithelial malignancies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis</measure>
    <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology for fallopian tube involvement at the subject level. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovary Cancer</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Fallopian Tube Adenocarcinoma</condition>
  <condition>High Grade Serous Carcinoma</condition>
  <condition>Peritoneal Carcinoma</condition>
  <condition>Peritoneal Neoplasms</condition>
  <condition>Adnexal Mass</condition>
  <condition>Ovarian Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hysteroscopic cell sampling of the fallopian tube</intervention_name>
    <description>Hysteroscopic fallopian tube biopsy</description>
    <other_name>Cytuity</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue and Cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are scheduled to undergo a salpingo-oophorectomy or salpingectomy because of a&#xD;
        pelvic mass suspicious for malignancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is medically cleared for surgery&#xD;
&#xD;
          2. Subject is scheduled to undergo salpingo-oophorectomy or salpingectomy for a pelvic&#xD;
             mass suspicious for malignancy&#xD;
&#xD;
          3. Subject must be 18 years of age&#xD;
&#xD;
          4. Subject must be able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to hysteroscopy&#xD;
&#xD;
          2. Acute pelvic inflammatory disease&#xD;
&#xD;
          3. Active or recent lower pelvic infection&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Delivery or termination of a pregnancy in the past 6 weeks&#xD;
&#xD;
          6. Known tubal obstruction&#xD;
&#xD;
          7. Tubal ligation&#xD;
&#xD;
          8. Invasive carcinoma of the cervix or endometrium&#xD;
&#xD;
          9. Intolerance of anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted L Anderson, MD,PhD,FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Health Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <results_first_submitted>October 27, 2020</results_first_submitted>
  <results_first_submitted_qc>December 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salpingo-oophorectomy</keyword>
  <keyword>salpingectomy</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>high grade serous carcinoma</keyword>
  <keyword>hysteroscopic biopsy</keyword>
  <keyword>fallopian tube cell collection</keyword>
  <keyword>peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03593681/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cytuity Cytological Evaluation</title>
          <description>Those subjects enrolled in the study, with hysteroscope placed, ostia visualized, and adequate Cytuity cell sample collected.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inadequate sample collected</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hysteroscope attempted but unable to find ostia</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Procedure not attempted</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytuity Cytological Evaluation</title>
          <description>Subjects from whom a signed informed consent form was obtained.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.2" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement</title>
        <description>Evaluate the sensitivity and specificity of the cytological samples collected from the fallopian tube in determining the presence or absence of malignancy for fallopian tube involvement as compared to the surgical histology results. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
        <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
        <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity - Proportion of Cytuity Cell Samples That Correctly Identify the Presence of Disease</title>
            <description>The number of true positive Cytuity cell samples divided by the number of true positives and the number of false negatives.</description>
          </group>
          <group group_id="O2">
            <title>Specificity - Proportion of Cytuity Cell Samples That Correctly Identify the Absence of Disease</title>
            <description>The number of true negative Cytuity cell samples divided by the number of true negatives and the number of false positives.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement</title>
          <description>Evaluate the sensitivity and specificity of the cytological samples collected from the fallopian tube in determining the presence or absence of malignancy for fallopian tube involvement as compared to the surgical histology results. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
          <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
          <units>Proportion of Cytuity Cell Samples</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Cytuity Cell Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="NA"/>
                <count group_id="O2" value="NA"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cytuity Cell Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".143" lower_limit=".029" upper_limit=".479"/>
                    <measurement group_id="O2" value=".959" lower_limit=".911" upper_limit=".981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PPV, NPV and Diagnostic Accuracy for Fallopian Tube Involvement</title>
        <description>Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries and fallopian tube for fallopian tube involvement. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
        <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
        <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PPV - Proportion of True Positive Results for Fallopian Tube Involvement</title>
            <description>The proportion of positive Cytuity cell samples that came from a fallopian tube found to have histology positive for malignancy and/or a corresponding ovary found to have histology positive for malignancy</description>
          </group>
          <group group_id="O2">
            <title>NPV - Proportion of True Negative Results for Fallopian Tube Involvement</title>
            <description>The proportion of negative Cytuity cell samples that came from a fallopian tube found to have histology negative for malignancy and a corresponding ovary found to have histology negative for malignancy</description>
          </group>
          <group group_id="O3">
            <title>Diagnostic Accuracy - Proportion of Accurate Diagnoses</title>
            <description>The proportion of Cytuity cell sample results that conformed to the correct diagnosis as determined by the surgical histology results</description>
          </group>
        </group_list>
        <measure>
          <title>PPV, NPV and Diagnostic Accuracy for Fallopian Tube Involvement</title>
          <description>Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries and fallopian tube for fallopian tube involvement. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
          <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
          <units>Proportion of Cytuity Cell Samples</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Cytuity Cell Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="NA"/>
                <count group_id="O2" value="NA"/>
                <count group_id="O3" value="NA"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cytuity Cell Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.221" lower_limit="0.032" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.932" lower_limit=".877" upper_limit=".963"/>
                    <measurement group_id="O3" value=".894" lower_limit=".834" upper_limit=".934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Fallopian Tube</title>
        <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the fallopian tube.</description>
        <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
        <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity - Proportion of Cytuity Cell Samples That Correctly Identify the Presence of Disease</title>
            <description>The number of true positive Cytuity cell samples divided by the number of true positive and the number of false negatives</description>
          </group>
          <group group_id="O2">
            <title>Specificity - Proportion of Cytuity Cell Samples That Correctly Identify the Absence of Disease</title>
            <description>The number of true negative Cytuity cell samples divided by the number of true negatives and the number of false positives</description>
          </group>
          <group group_id="O3">
            <title>PPV - Proportion of True Positive Results for Fallopian Tube Pathology</title>
            <description>The proportion of positive Cytuity cell samples that came from a fallopian tube also found to have histology positive for malignancy</description>
          </group>
          <group group_id="O4">
            <title>NPV - Proportion of True Negative Results for Fallopian Tube Pathology</title>
            <description>The proportion of negative Cytuity cell samples that came from a fallopian tube also found to have histology negative for malignancy</description>
          </group>
          <group group_id="O5">
            <title>Diagnostic Accuracy - Proportion of Accurate Diagnoses</title>
            <description>The proportion of Cytuity cell sample results that conformed to the correct diagnosis as determined by the surgical histology results</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Fallopian Tube</title>
          <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the fallopian tube.</description>
          <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
          <units>Proportion of Cytuity Cell Samples</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Cytuity Cell Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="NA"/>
                <count group_id="O2" value="NA"/>
                <count group_id="O3" value="NA"/>
                <count group_id="O4" value="NA"/>
                <count group_id="O5" value="NA"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cytuity Cell Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="161"/>
                <count group_id="O5" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".077" lower_limit=".008" upper_limit=".467"/>
                    <measurement group_id="O2" value=".952" lower_limit=".903" upper_limit=".977"/>
                    <measurement group_id="O3" value=".108" lower_limit=".008" upper_limit=".652"/>
                    <measurement group_id="O4" value=".932" lower_limit=".877" upper_limit=".963"/>
                    <measurement group_id="O5" value=".888" lower_limit=".826" upper_limit=".929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Ovaries</title>
        <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries for epithelial malignancies.</description>
        <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
        <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity - Proportion of Cytuity Cell Samples That Correctly Identify the Presence of Disease</title>
            <description>Number of true positive Cytuity cell samples divided by the number of true positives and the number of false negatives</description>
          </group>
          <group group_id="O2">
            <title>Specificity - Proportion of Cytuity Cell Samples That Correctly Identify the Absence of Disease</title>
            <description>The number of true negative Cytuity cell samples divided by the number of true negatives and the number of false positives</description>
          </group>
          <group group_id="O3">
            <title>PPV - Proportion of True Positive Results for Ovary Pathology for Epithelial Malignancy</title>
            <description>The proportion of positive Cytuity cell samples that came from a fallopian tube adjacent to a corresponding ovary found to have histology positive for malignancy</description>
          </group>
          <group group_id="O4">
            <title>NPV - Proportion of True Negatives for Ovary Pathology for Epithelial Malignancy</title>
            <description>The proportion of negative Cytuity cell samples that came from a fallopian tube adjacent to a corresponding ovary found to have histology truly negative for malignancy</description>
          </group>
          <group group_id="O5">
            <title>Diagnostic Accuracy - Proportion of Accurate Diagnoses</title>
            <description>The proportion of Cytuity cell sample results that conformed to the correct diagnosis as determined by the surgical histology results</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Ovaries</title>
          <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries for epithelial malignancies.</description>
          <population>The number of Cytuity cell samples, not participants, was used for these endpoint analyses.</population>
          <units>Proportion of Cytuity Cell Samples</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Cytuity Cell Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="NA"/>
                <count group_id="O2" value="NA"/>
                <count group_id="O3" value="NA"/>
                <count group_id="O4" value="NA"/>
                <count group_id="O5" value="NA"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cytuity Cell Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".091" lower_limit=".02" upper_limit=".331"/>
                    <measurement group_id="O2" value=".963" lower_limit=".913" upper_limit=".985"/>
                    <measurement group_id="O3" value=".281" lower_limit=".04" upper_limit=".788"/>
                    <measurement group_id="O4" value=".883" lower_limit=".812" upper_limit=".929"/>
                    <measurement group_id="O5" value=".851" lower_limit=".779" upper_limit=".902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis</title>
        <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology for fallopian tube involvement at the subject level. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
        <time_frame>At the time of the scheduled salpingectomy or salpingo-oophorectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity - Subjects in Which the Cytuity Correctly Identified the Presence of Disease</title>
            <description>Number of subjects with true positive Cytuity cell samples divided by the number of subjects with true positives and the number of subjects with false negatives</description>
          </group>
          <group group_id="O2">
            <title>Specificity - Subjects in Which the Cytuity Correctly Identified the Absence of Disease</title>
            <description>The number of subjects with true negative Cytuity cell samples divided by the number of subjects with true negatives and the number of subjects with false positives</description>
          </group>
          <group group_id="O3">
            <title>PPV - True Positive Results for Fallopian Tube Involvement on Subject Level</title>
            <description>The number of subjects with a positive Cytuity cell sample and a fallopian tube and/or corresponding ovary with histology positive for malignancy</description>
          </group>
          <group group_id="O4">
            <title>NPV - True Negative Results for Fallopian Tube Involvement on Subject Level</title>
            <description>The number of subjects with a negative Cytuity cell sample and a fallopian tube and corresponding ovary with histology negative for malignancy</description>
          </group>
          <group group_id="O5">
            <title>Diagnostic Accuracy - Subjects With Accurate Diagnoses</title>
            <description>The number of subjects with a Cytuity cell sample result that conformed to the correct diagnosis on a subject level as determined by the surgical histology results</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis</title>
          <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology for fallopian tube involvement at the subject level. Fallopian tube involvement was defined as: 1. Malignant cells that originated in the fallopian tube, detected by the surgical histology results from the fallopian tube. 2. Malignant cells that have migrated to the fallopian tube, detected by surgical histology results of the ovaries or fallopian tube.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events occurring from the time the hysteroscope entered the subject until study exit (defined as 24 hours post-Cytuity use or discharge, whichever occurs first).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated Subjects</title>
          <description>Subjects who signed the informed consent and had hysteroscope placement attempted</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Uterine Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Fallopian Tube perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Project Manager</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>612-209-9532</phone>
      <email>blake.hedstrom@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

